{"id":"smoothened","name":"Smoothened (hedgehog pathway)","symbol":"SMO","route":"/targets/smoothened/","asOf":"2026-09-08","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11119","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128602","uniprot":"https://www.uniprot.org/uniprotkb/Q99835/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q99835","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5971","open-targets":"https://platform.opentargets.org/target/ENSG00000128602","civic":"https://civicdb.org/genes/6608/summary","oncokb":"https://www.oncokb.org/gene/SMO","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SMO","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=SMO","depmap":"https://depmap.org/portal/gene/SMO?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000128602-SMO","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/6608","omim":"https://www.omim.org/entry/601500"}],"products":[{"id":"glasdegib","name":"Glasdegib","status":"approved","modality":"Small-molecule smoothened (hedgehog) inhibitor","route":"/drugs/glasdegib/"},{"id":"patidegib","name":"Patidegib","status":"phase-3","modality":"Topical hedgehog pathway (SMO) inhibitor gel","route":"/drugs/patidegib/"},{"id":"sonidegib","name":"Sonidegib","status":"approved","modality":"Small-molecule smoothened inhibitor","route":"/drugs/sonidegib/"},{"id":"vismodegib","name":"Vismodegib","status":"approved","modality":"Small-molecule smoothened (hedgehog) inhibitor","route":"/drugs/vismodegib/"}],"trials":[{"id":"nct03416179","name":"A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia","nct":"NCT03416179","phase":"3","status":"completed"},{"id":"nct04842604","name":"Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML","nct":"NCT04842604","phase":"3","status":"completed"},{"id":"nct06050122","name":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","nct":"NCT06050122","phase":"3","status":"completed"},{"id":"nct04093505","name":"Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)","nct":"NCT04093505","phase":"3"},{"id":"nct03784014","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","nct":"NCT03784014","phase":"3","status":"completed"},{"id":"determine-trial","name":"DETERMINE","nct":"NCT05722886","phase":"platform","status":"recruiting"},{"id":"patidegib-gel-gorlin-phase-2","name":"Patidegib gel in Gorlin syndrome (phase 2A)","nct":"NCT02762084","phase":"2","status":"mixed"},{"id":"cupisco","name":"CUPISCO","nct":"NCT03498521","phase":"2","status":"positive"},{"id":"vismoneo","name":"VISMONEO (vismodegib before surgery for locally advanced basal cell carcinoma)","nct":"NCT02667574","phase":"2","status":"positive"},{"id":"mypathway","name":"MyPathway","nct":"NCT02091141","phase":"2","status":"completed"},{"id":"stevie","name":"STEVIE (vismodegib in ordinary practice)","nct":"NCT01367665","phase":"2","status":"mixed"},{"id":"bolt","name":"BOLT","nct":"NCT01327053","phase":"2","status":"positive"},{"id":"erivance","name":"ERIVANCE BCC","nct":"NCT00833417","phase":"2","status":"positive"},{"id":"sjmb12","name":"SJMB12","nct":"NCT01878617","phase":"2","status":"active"},{"id":"nct06344052","name":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma","nct":"NCT06344052","phase":"2","status":"recruiting"}],"pathways":["basal-cell-carcinoma-signalling","caf-activation-desmoplasia","proteoglycans-in-cancer"],"companies":["novartis","pellepharm","pfizer","roche-genentech","sun-pharma"],"keyPapers":["paper-bonilla-nat-genet"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}